Showing 1,530 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

New & experimental HIV treatments

Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%

Editor's pick
Motley Fool
24 March 2019
Government, leadership & policy

Trump’s Proposed Budget Undermines His H.I.V. Plan, Experts Say

Editor's pick
The New York Times
14 March 2019
PrEP policies & guidelines

Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

Editor's pick
FiercePharma
14 March 2019
Finance & funding

Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes

Editor's pick
Kaiser Health News
5 March 2019
PrEP

Should the NIH Break HIV Prevention Drug Truvada's Patent?

Editor's pick
Fortune
5 March 2019
Pharmaceutical industry

Hepatitis C Treatment Market to Exceed US$ 71.13 Bn by the end of 2024

Editor's pick
Honest Businessman
4 March 2019
Finance & funding

A new way to pay for innovative drugs, provide universal access and not break the bank

Editor's pick
The Conversation
28 February 2019
Access to healthcare

Analysis: How a cutting edge medicine made it to South Africa’s new ARV tender

Editor's pick
Spotlight
27 February 2019
Access to healthcare

The Good Law Project threatens Judicial Review of Serious Shortage Protocols

Editor's pick
Good Law Project
24 February 2019
Access to healthcare

US: The struggle to maintain access to lifesaving HIV meds

Editor's pick
Washington Blade
24 February 2019
Pharmaceutical industry

The Trump Administration's Drug Pricing Proposals for People With HIV, Explained

Editor's pick
The Body
20 February 2019
Pharmaceutical industry

Trump's HIV pledge comes as Gilead pumps cash into Truvada for PrEP

Editor's pick
FiercePharma
7 February 2019
Generic medicines

CHMP recommends for approval a generic version of atazanavir

Editor's pick
EATG
5 February 2019
New & experimental HIV treatments

CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial

Editor's pick
Proactive Investors USA & Canada
4 February 2019
Pharmaceutical industry

HIV Drug Prices Keep Rising. Why Is No One Talking About It?

Editor's pick
The Body
30 January 2019
Pharmaceutical industry

The Economics Of Cures - Gilead At A Turning Point

Editor's pick
Seeking Alpha
28 January 2019
Elimination of hepatitis C

UK court dismisses AbbVie's legal challenge against the NHS

Editor's pick
The Lancet (free registration required)
25 January 2019
Elimination of hepatitis C

NHS England’s plan to eliminate Hepatitis C decisively backed by High Court

Editor's pick
NHS England
18 January 2019
Low CD4 count

‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

Editor's pick
STAT
8 January 2019
Pharmaceutical industry

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

Editor's pick
Reuters UK
8 January 2019
Generic medicines

Cipla recalls 4,800 bottles of anti-HIV tablets from American market

Editor's pick
Business Today
30 December 2018
Access to healthcare

UK-CAB statement on Brexit, HIV and access to medicines

Editor's pick
UK-CAB
20 December 2018
Finance & funding

So Close, Yet So Far: Why is HIV/AIDS Funding Decreasing?

Editor's pick
Inside Philanthropy
19 December 2018
Pharmaceutical industry

Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

Editor's pick
BioPharma Dive
12 December 2018